Results 51 to 60 of about 92,066 (229)

Cefepime exposure in prolonged or intermittent infusion in critically ill children

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Cefepime is commonly used in critically ill children for whom there is a high between‐subject variability. To reach the therapeutic pharmacokinetic (PK) target in critically ill patients, prolonged infusion of beta‐lactams seems to be the most efficient.
Marc Hobeika   +12 more
wiley   +1 more source

COMPARISON OF EMPIRIC ANTIBIOTIC ESCALATION THERAPY WITH VANCOMYCIN (VAN) VERSUS LINEZOLID (LIN) IN PATIENTS WITH FEBRILE NEUTROPENIA

open access: yesMediterranean Journal of Hematology and Infectious Diseases, 2022
Background: In febrile neutropenia linezolid (LIN) and also vancomycin (VAN) can be used if a gram-positive infection is suspected. Interestingly there is no literature in which both are compared in the setting of febrile neutropenia.
Karin Mayer   +4 more
doaj   +1 more source

A case series of necrotizing periodontal diseases in hospitalized patients: What hasn't been said yet?

open access: yesClinical Advances in Periodontics, EarlyView.
Abstract Background Necrotizing periodontal diseases (NPDs) are uncommon and severe inflammatory conditions characterized by tissue necrosis, painful ulceration, and rapid clinical progression, frequently associated with systemic immunosuppression. Limited data exist regarding their clinical presentation and management in hospital settings.
Osmaria Letthycia Carvalho Leal   +8 more
wiley   +1 more source

Total Neoadjuvant Treatment for Esophageal Adenocarcinoma With Oligometastases: TNT‐OES‐1 Trial

open access: yesInternational Journal of Cancer, EarlyView.
Total neoadjuvant therapy could combine the potentially strong systemic effect of FLOT chemotherapy with the good locoregional control of CROSS chemoradiotherapy. While total neoadjuvant therapy is increasingly used in rectal cancer, its potential in gastroesophageal cancer remains largely unexplored.
Charlène J. van der Zijden   +12 more
wiley   +1 more source

Pediatric Clostridiodes difficile infection with toxic megacolon successfully treated with fecal microbiota transplantation

open access: yesJPGN Reports, EarlyView.
Abstract The rising incidence of pediatric Clostridioides difficile infection (CDI), particularly in medically complex patients, calls for novel, individualized treatments. While fecal microbiota transplantation (FMT) is well‐described for recurrent CDI, this report describes the first pediatric case of fulminant CDI with toxic megacolon successfully ...
Dana McCarney   +3 more
wiley   +1 more source

Advances in management of low-risk febrile neutropenia

open access: yes, 2012
To describe and discuss the most recent advances in the management of low-risk febrile neutropenia in children with ...
Teuffel, Oliver   +3 more
core   +1 more source

Management of chemotherapy-associated febrile neutropenia [PDF]

open access: yes, 2009
The development of febrile neutropenia during a course of chemotherapy is not only a life-threatening complication, it can also lead to a decision to reduce chemotherapy intensity in subsequent treatment cycles, thus putting patient outcomes at risk ...
D Cameron, Cameron, D
core   +1 more source

Testicular Abscess an Unusual Cause for Febrile Neutropenia

open access: yesThe Scientific World Journal, 2008
Patients with good-risk disseminated testicular cancer are effectively managed with platinum-based chemotherapy. Febrile neutropenia is a dose-limiting event for many chemotherapy regimens.
Tal Grenader
doaj   +1 more source

Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma: Phase 1b dose‐escalation study

open access: yesBritish Journal of Haematology, EarlyView.
Summary Glofitamab was investigated with obinutuzumab/rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (G/R‐CHOP) in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma (B‐NHL) who had ≥1 prior obinutuzumab/rituximab‐containing therapy (NCT03467373). The primary end‐point was to determine the optimal biological dose of
William Townsend   +16 more
wiley   +1 more source

How I treat febrile neutropenia [PDF]

open access: yes, 2021
The management of febrile neutropenia is a backbone of the treatment of patients with hematologic malignancies, and has evolved over the past decades. This article reviews my approach to the evaluation and treatment of febrile neutropenic patients.
Marcio Nucci
core   +1 more source

Home - About - Disclaimer - Privacy